Reporter Virginia Hughes tells the story of Robert Getzenberg's discovery of a potential prostate cancer biomarker, EPCA-2. Since he discovered EPCA-2 a decade ago, he partnered with a biotech, Onconome, to develop a commercial test. No such test has emerged, and now the company is suing him for fraud. Hughes uses Getzenberg's case as a lens through which to see the entire prostate cancer biomarker field, which, so far, hasn't delivered on early promises.
Read "Markers of Dispute"
See the archived story and contest questionnaire in which the reporter writes about how this story was written.